Net Income

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.

Omaha-based platform SheSports adds five new athletes, expanding into softball and track to close the NIL compensation gap for women in non-revenue sports.

Quantum firm Zapata adds industry veterans to its board, signaling a strategic shift in the quantum race from hardware supremacy to software application.

Praesidian Capital unites iconic model train maker Lionel with hobby giant Round 2, creating a new collectibles empire focused on innovation and growth.

Agenus activates a key manufacturing pact with Zydus, scaling production for its promising BOT+BAL cancer therapy ahead of regulatory filings and market launch.

Assets of pioneering engineering firm Xytel Corp. go to auction after its closure, offering rare deals on high-demand industrial equipment.

As Zepp Health unveils its 2025 performance, all eyes are on its fight for profitability and market share against giants like Garmin and Apple.

After two decades of building a global beauty empire, It's a 10 founder Carolyn Aronson is recognized among America's most dynamic women leaders.

Real estate tech firm RESAAS hires Oak Hill Financial, signaling a major push to enhance market visibility and attract investment amid a volatile stock history.

Soluna Holdings is aggressively expanding from Bitcoin to AI, betting its future on turning wasted renewable energy into high-demand computing power.

With its CAR-T therapy achieving franchise profitability and treating 10,000 patients, Legend Biotech eyes overall profit and next-gen cancer treatments.

The EV maker reported a landmark non-GAAP operating profit in Q4 2025, fueled by record sales across its three brands and aggressive cost-cutting.

Tenax Therapeutics achieves a major clinical trial goal, moving its promising drug TNX-103 closer to becoming the first approved therapy for a deadly heart condition.

A new survey finds companies are dynamically adjusting investment hurdles in response to market chaos, leveraging technology to navigate an uncertain world.

Middle and high schoolers are building AI to aid surgery and streamline recycling, signaling a major shift from college prep to real-world innovation.

Celebrating 80 years, Aveeno renews its foundational ties with Mayo Clinic, launching a new era of oat science research for compromised skin.

Stonegate Investment Group's $6 billion move to NewEdge's 'Pillar Channel' highlights a new model for advisor monetization and client-centric growth.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.